Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...
As newborns are exposed to measles in Texas, healthcare workers are working to mitigate the outbreak and immunizing children as young as three days old.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback